Are Bisphosphonates Safe for Gaucher Disease Bone Loss?
At a Glance
Bisphosphonates are not the first-choice treatment for bone loss in Gaucher disease. Instead, doctors prefer Enzyme Replacement Therapy (ERT) or Substrate Reduction Therapy (SRT) to treat the underlying cause. Bisphosphonates carry specific bone risks and require specialist management.
If you have Gaucher disease and are experiencing bone thinning or osteoporosis, standard bone-building medications like bisphosphonates are not usually the first step in your treatment. Instead, your doctor will likely focus on treating the underlying cause of the bone loss using Enzyme Replacement Therapy (ERT) or Substrate Reduction Therapy (SRT) [1][2]. While bisphosphonates are sometimes prescribed for severe bone thinning in Gaucher disease, they must be managed very carefully by a Gaucher specialist because bone disease in Gaucher patients behaves differently than standard, age-related osteoporosis [3][4].
How Gaucher Bone Disease is Different
In standard osteoporosis, bones lose density primarily because of aging, hormonal changes (like estrogen dropping after menopause), or a lack of calcium and vitamin D [3]. However, bone loss in Gaucher disease is caused by the buildup of Gaucher cells—immune cells stuffed with a specific fatty substance (glucosylceramide)—inside the bone marrow [5].
These cells crowd the marrow and trigger a unique type of localized inflammation [5][3]. This inflammation disrupts the normal process of bone remodeling, leading to generalized bone thinning (osteopenia or osteoporosis) and sometimes causing severe complications like bone crises, focal bone lesions, and osteonecrosis (bone tissue death due to lack of blood supply) [3][6][7]. Because the root cause of the bone loss is different, the approach to treating it must also be different.
ERT and SRT: The First Line of Defense
The primary and most effective way to improve bone density and prevent skeletal complications in Gaucher disease is to clear the Gaucher cells out of the bone marrow [8][9].
- Enzyme Replacement Therapy (ERT): ERT provides the missing enzyme to help break down the fatty substances, which reduces the burden of storage cells and secondary inflammation in the bones [8][10]. This can improve bone mineral density and reduce bone marrow burden over time [11].
- Substrate Reduction Therapy (SRT): SRT, such as eliglustat, works by slowing down the production of the fatty substances so they do not build up as quickly. SRT has also demonstrated long-term effectiveness in improving bone mineral density and reducing skeletal complications [1][12].
These therapies treat the underlying disease rather than just the symptom of bone thinning [13].
The Role and Risks of Bisphosphonates
Bisphosphonates are a class of medications (like alendronate or zoledronic acid) commonly used to treat standard osteoporosis by slowing down the cells that break down bone [9][14].
While they might be considered for Gaucher patients with severe bone thinning, they are generally viewed as a secondary option and must be used with extreme caution [2][4]. The reasons for this caution include:
- Atypical Femoral Fractures: There is evidence that Gaucher patients who take bisphosphonates for several years may have a higher risk of developing atypical (unusual) fractures in the femur (thigh bone) [4].
- Osteonecrosis of the Jaw: Long-term use of bisphosphonates is associated with a risk of osteonecrosis of the jaw in the general population [6]. Since Gaucher disease itself already increases the risk of osteonecrosis and bone pathology, doctors must be very careful when adding a medication that carries a similar risk [6][4].
What You Can Do
If a bone density scan (DXA scan) shows that you have osteoporosis or osteopenia:
- Talk to your Gaucher specialist: Do not start standard osteoporosis medications prescribed by a general practitioner without consulting the specialist who manages your Gaucher disease.
- Review your current treatment: If you are already on ERT or SRT, your doctor will monitor whether your bone density is stabilizing or improving [2]. It can take years for bones to rebuild, so do not panic if your next scan does not show immediate improvement.
- Ensure adequate nutrition: Continue to ensure you are getting enough Vitamin D and calcium, as these are the building blocks your body needs to create new bone once ERT or SRT has cleared out the Gaucher cells.
- Discuss safe exercise: Ask your doctor about safe, weight-bearing exercises to support bone health, ensuring that any activity is approved by your specialist to avoid injury.
Common questions in this guide
Why are bisphosphonates not the first choice for bone loss in Gaucher disease?
What are the risks of taking bisphosphonates if I have Gaucher disease?
Will Enzyme Replacement Therapy (ERT) improve my bone density?
What should I do if a DXA scan shows I have osteoporosis from Gaucher disease?
Questions for Your Doctor
6 questions
- •Is my current dose of ERT or SRT effectively managing my bone marrow burden and bone density?
- •What were the specific T-scores or Z-scores on my most recent bone density scan, and how have they changed over time?
- •Should we order a blood test to check my Vitamin D and calcium levels?
- •Do I have any signs of focal bone lesions or osteonecrosis that we need to monitor?
- •What types of weight-bearing exercises are safe for my current level of bone health?
- •If my bone density continues to decline despite ERT/SRT, what are the safest secondary options for a Gaucher patient?
Questions for You
3 questions
- •Have I experienced any unexplained, deep bone pain or a 'bone crisis' recently?
- •Am I consistently taking my ERT or SRT as prescribed?
- •Do I have other non-Gaucher risk factors for osteoporosis, such as a family history, being postmenopausal, or a history of taking steroid medications?
References
References (14)
- 1
Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM, Charrow J, Lukina E, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2023; (25(2)):100329 doi:10.1016/j.gim.2022.10.011.
PMID: 36469032 - 2
GBA1 as a risk gene for osteoporosis in the specific populations and its role in the development of Gaucher disease.
Wang CH, Huang YN, Liao WL, et al.
Orphanet journal of rare diseases 2024; (19(1)):144 doi:10.1186/s13023-024-03132-x.
PMID: 38575988 - 3
Diet, β-glucocerebrosidase deficiency, and Parkinson's disease.
Shayman JA
Journal of lipid research 2024; (65(12)):100689 doi:10.1016/j.jlr.2024.100689.
PMID: 39490443 - 4
Bone development and remodeling in metabolic disorders.
Serra-Vinardell J, Roca-Ayats N, De-Ugarte L, et al.
Journal of inherited metabolic disease 2020; (43(1)):133-144 doi:10.1002/jimd.12097.
PMID: 30942483 - 5
Pathogenesis of Bone Alterations in Gaucher Disease: The Role of Immune System.
Mucci JM, Rozenfeld P
Journal of immunology research 2015; (2015()):192761 doi:10.1155/2015/192761.
PMID: 26064996 - 6
Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis.
D'Amore S, Poole KE, Ramaswami U, et al.
Metabolites 2024; (14(11)) doi:10.3390/metabo14110601.
PMID: 39590837 - 7
Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.
Degnan AJ, Ho-Fung VM, Ahrens-Nicklas RC, et al.
Insights into imaging 2019; (10(1)):70 doi:10.1186/s13244-019-0743-5.
PMID: 31289964 - 8
An Overview of Gaucher Disease.
Méndez-Cobián DA, Guzmán-Silahua S, García-Hernández D, et al.
Diagnostics (Basel, Switzerland) 2024; (14(24)) doi:10.3390/diagnostics14242840.
PMID: 39767201 - 9
Gaucher Disease for Hematologists
Özdemir GN, Gündüz E
Turkish journal of haematology : official journal of Turkish Society of Haematology 2022; (39(2)):136-139 doi:10.4274/tjh.galenos.2021.2021.0683.
PMID: 35439918 - 10
Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.
Van Rossum A, Holsopple M
Hospital pharmacy 2016; (51(7)):553-63 doi:10.1310/hpj5107-553.
PMID: 27559188 - 11
Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy.
Beshlawy AE, Murugesan V, Mistry PK, Eid K
Molecular genetics and metabolism reports 2019; (20()):100490 doi:10.1016/j.ymgmr.2019.100490.
PMID: 31309038 - 12
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK, Lukina E, Ben Turkia H, et al.
American journal of hematology 2017; (92(11)):1170-1176 doi:10.1002/ajh.24877.
PMID: 28762527 - 13
Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.
Herrera S, Pérez-López J, Moltó-Abad M, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2017; (32(7)):1575-1581 doi:10.1002/jbmr.3121.
PMID: 28263001 - 14
Gaucher disease - therapeutic aspects in Romania.
Chis BA, Chis AF, Dumitrascu DL
Medicine and pharmacy reports 2021; (94(Suppl No 1)):S51-S53 doi:10.15386/mpr-2230.
PMID: 34527911
This page provides educational information about bone health in Gaucher disease. It does not replace professional medical advice. Always consult your Gaucher specialist before starting or stopping any osteoporosis medications.
Get notified when new evidence is published on Gaucher Disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.